Phase III Study to Compared Preoperative and Postoperative With FOFLOX4 Chemotherapy and Postoperative With FOFLOX4 Chemotherapy in Patients With Resectable Liver Metastasis From Colorectal Cancer
To investigate the three-year progression free survival (PFS) advantage of FOLFOX4 in the
treatment of resectable metastatic colorectal cancer.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
progression free survival (PFS)
3 years
No
Feng Lin, Dr
Principal Investigator
Guangdong General Hospital
China: Ethics Committee
VORP019
NCT01035385
September 2009
December 2015
Name | Location |
---|